Legal Action
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Track global pharma legal actions, patent litigation, regulatory challenges, and IP disputes impacting drug development and market access. Stay informed.
Showing 1–2 of 2 articles
Quick answer
NovaPharmaNews Legal Action hub for NMPA covers 2 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
Atara Biotherapeutics Class Action Lawsuit Filed: ATRA Stockholders May Recover Investment Losses from May 2024-January 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.